A COMPARISON OF KU0063794, A DUAL MTORC1 AND MTORC2 INHIBITOR, AND TEMSIROLIMUS IN PRECLINICAL RENAL CELL CARCINOMA MODELS

被引：0
|
作者：
Zhang, Hao
Berel, Dror
Wang, Yanping
Figlin, Robert
Kim, Hyung
机构：
来源：
JOURNAL OF UROLOGY | 2012年 / 187卷 / 04期
关键词：
D O I：
10.1016/j.juro.2012.02.359
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
300
引用
收藏
页码：E121 / E122
页数：2
相关论文
共 50 条
  • [1] A Comparison of Ku0063794, a Dual mTORC1 and mTORC2 Inhibitor, and Temsirolimus in Preclinical Renal Cell Carcinoma Models
    Zhang, Hao
    Berel, Dror
    Wang, Yanping
    Li, Ping
    Bhowmick, Neil A.
    Figlin, Robert A.
    Kim, Hyung L.
    PLOS ONE, 2013, 8 (01):
  • [2] Combined Targeting of mTORC1 and mTORC2 Synergistically Inhibits Proliferation of Hepatocellular Carcinoma Cells: Effects of Everolimus and Ku0063794
    Kim, Say-June
    Choi, Ho-Joong
    Kim, Dong-Goo
    LIVER TRANSPLANTATION, 2014, 20 : S235 - S235
  • [3] KU0063794, a Dual mTORC1 and mTORC2 Inhibitor, Reduces Neural Tissue Damage and Locomotor Impairment After Spinal Cord Injury in Mice
    Marika Cordaro
    Irene Paterniti
    Rosalba Siracusa
    Daniela Impellizzeri
    Emanuela Esposito
    Salvatore Cuzzocrea
    Molecular Neurobiology, 2017, 54 : 2415 - 2427
  • [4] KU0063794, a Dual mTORC1 and mTORC2 Inhibitor, Reduces Neural Tissue Damage and Locomotor Impairment After Spinal Cord Injury in Mice
    Cordaro, Marika
    Paterniti, Irene
    Siracusa, Rosalba
    Impellizzeri, Daniela
    Esposito, Emanuela
    Cuzzocrea, Salvatore
    MOLECULAR NEUROBIOLOGY, 2017, 54 (04) : 2415 - 2427
  • [5] Dramatic antitumor effects of the dual mTORC1 and mTORC2 inhibitor AZD2014 in hepatocellular carcinoma
    Liao, Hui
    Huang, Yu
    Guo, Botang
    Liang, Bo
    Liu, Xincheng
    Ou, Huohui
    Jiang, Chenglong
    Li, Xianghong
    Yang, Dinghua
    AMERICAN JOURNAL OF CANCER RESEARCH, 2015, 5 (01): : 125 - 139
  • [6] The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models
    Pignochino, Ymera
    Dell'Aglio, Carmine
    Basirico, Marco
    Capozzi, Federica
    Soster, Marco
    Marchio, Serena
    Bruno, Stefania
    Gammaitoni, Loretta
    Sangiolo, Dario
    Torchiaro, Erica
    D'Ambrosio, Lorenzo
    Fagioli, Franca
    Ferrari, Stefano
    Alberghini, Marco
    Picci, Piero
    Aglietta, Massimo
    Grignani, Giovanni
    CLINICAL CANCER RESEARCH, 2013, 19 (08) : 2117 - 2131
  • [7] Discovery of AZD3147: A Potent, Selective Dual Inhibitor of mTORC1 and mTORC2
    Pike, Kurt G.
    Morris, Jeff
    Ruston, Linette
    Pass, Sarah L.
    Greenwood, Ryan
    Williams, Emma J.
    Demeritt, Julie
    Culshaw, Janet D.
    Gill, Kristy
    Pass, Martin
    Finlay, M. Raymond V.
    Good, Catherine J.
    Roberts, Craig A.
    Currie, Gordon S.
    Blades, Kevin
    Eden, Jonathan M.
    Pearson, Stuart E.
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (05) : 2326 - 2349
  • [8] mTORC1 and mTORC2 as regulators of cell metabolism in immunity
    Linke, Monika
    Fritsch, Stephanie Deborah
    Sukhbaatar, Nyamdelger
    Hengstschlaeger, Markus
    Weichhart, Thomas
    FEBS LETTERS, 2017, 591 (19): : 3089 - 3103
  • [9] A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin
    Huang, Yu
    Xi, Qingsong
    Chen, Yu
    Wang, Jing
    Peng, Ping
    Xia, Shu
    Yu, Shiying
    ANTI-CANCER DRUGS, 2013, 24 (09) : 889 - 898
  • [10] The combination of the dual mTORC1/mTORC2 inhibitor AZD2014 and paclitaxel in human ovarian cancer models
    Stewart, Adam
    Thavasu, Parames
    Heaton, Simon
    Banerjee, Susana
    Kaye, Stan B.
    Banerji, Udai
    CANCER RESEARCH, 2012, 72
12345